Cochran Christopher P. 4

What Happened
Christopher P. Cochran, a director of Coeptis Therapeutics Holdings, exercised stock options to acquire 5,700 shares at an exercise price of $10.56 per share (total cash/price basis $60,192) on February 11, 2026. On the same date he was also granted 3,250 restricted shares (reported at $0 value) as part of a grant/award.

Key Details

• Transaction date: 2026-02-11 (reported on Form 4 filed 2026-02-13; appears timely filed).
• Option exercise: 5,700 shares acquired @ $10.56 per share; aggregate $60,192. (Derivative code M) — footnote F1 indicates $10.56 is the exercise price.
• Restricted stock grant: 3,250 shares @ $0.00 (aggregate $0). (Grant code A) — footnote F2 notes the restricted stock was issued in connection with an option-exchange program where underwater options were surrendered.
• No sale of the newly acquired shares is reported in this filing.
• Shares owned after the transactions: not specified in the supplied filing details.
• No 10b5-1 plan, tax-withholding sale (F), or late-filing indicator noted in the provided data.

Context
This filing shows an acquisition of shares via option exercise plus a grant of restricted stock under an option-exchange program. An exercise + restricted-stock grant are acquisitions (not sales); purchases and grants can be viewed by investors as a stronger signal than routine sales, but filings do not state the insider’s motivations.